Literature DB >> 15964125

Proteome analysis of gelatin-bound urinary proteins from patients with bladder cancers.

Minoru Saito1, Masafumi Kimoto, Teruo Araki, Yukie Shimada, Ryoji Fujii, Ken Oofusa, Michihiro Hide, Tsuguru Usui, Katsutoshi Yoshizato.   

Abstract

OBJECTIVES: Proteome analysis with protein separation by two-dimensional polyacrylamide gel electrophoresis (2-D PAGE) and mass spectrometric measurement is utilized for comprehensive identification of proteins in various biological samples. However, this technique has not been widely applied for the analysis of body fluid for clinical assessments, because large amounts of proteins in fluid such as albumin and globulin hinder the detection of small amounts of proteins with high clinical values. The aim of the present study is to develop a method of proteomic analysis for urine of patients with bladder cancers.
MATERIALS AND METHODS: Urine samples collected from 40 patients with bladder cancers, 32 healthy volunteers, and 7 old volunteers with benign prostate hypertrophy were treated with gelatin-beads as a group-specific affinity carrier. The gelatin-bound proteins were subjected to the proteome analysis.
RESULTS: Various amounts of matrix metalloproteinase-2 (MMP-2), -9 (MMP-9), fibronectin (FN), and their fragments were identified on 2-D PAGE gels from cancer-bearing patients, but not from normal individuals. Importantly, not only total amounts of these proteins, but also patterns of their distributions on the gels were well matched with the extent of invasion diagnosed with histopathological examinations. Thus, the score including such qualitative patterning of these proteins predicts pathological stages of the cancer.
CONCLUSION: The proteomic analysis with gelatin-affinity purification of urine samples is useful not only for the diagnosis of bladder cancers, but also for estimating the extent of tumor invasion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964125     DOI: 10.1016/j.eururo.2005.04.028

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  21 in total

Review 1.  Urinary proteomics as a novel tool for biomarker discovery in kidney diseases.

Authors:  Jing Wu; Yi-ding Chen; Wei Gu
Journal:  J Zhejiang Univ Sci B       Date:  2010-04       Impact factor: 3.066

Review 2.  Proteomic studies of urinary biomarkers for prostate, bladder and kidney cancers.

Authors:  Steven L Wood; Margaret A Knowles; Douglas Thompson; Peter J Selby; Rosamonde E Banks
Journal:  Nat Rev Urol       Date:  2013-02-26       Impact factor: 14.432

Review 3.  Molecular diagnostic trends in urological cancer: biomarkers for non-invasive diagnosis.

Authors:  V Urquidi; C J Rosser; S Goodison
Journal:  Curr Med Chem       Date:  2012       Impact factor: 4.530

4.  Urinary glycoprotein biomarker discovery for bladder cancer detection using LC/MS-MS and label-free quantification.

Authors:  Na Yang; Shun Feng; Kerby Shedden; Xiaolei Xie; Yashu Liu; Charles J Rosser; David M Lubman; Steven Goodison
Journal:  Clin Cancer Res       Date:  2011-04-01       Impact factor: 12.531

5.  Tumor-specific urinary matrix metalloproteinase fingerprinting: identification of high molecular weight urinary matrix metalloproteinase species.

Authors:  Roopali Roy; Gwendolyn Louis; Kevin R Loughlin; Dmitri Wiederschain; Susan M Kilroy; Carolyn C Lamb; David Zurakowski; Marsha A Moses
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

Review 6.  Proteomics and opportunities for clinical translation in urological disease.

Authors:  Ali R Vaezzadeh; Hanno Steen; Michael R Freeman; Richard S Lee
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

Review 7.  Challenges of using mass spectrometry as a bladder cancer biomarker discovery platform.

Authors:  Eric Schiffer; Harald Mischak; Dan Theodorescu; Antonia Vlahou
Journal:  World J Urol       Date:  2008-01-04       Impact factor: 4.226

Review 8.  Urinary proteomic profiling for diagnostic bladder cancer biomarkers.

Authors:  Steve Goodison; Charles J Rosser; Virginia Urquidi
Journal:  Expert Rev Proteomics       Date:  2009-10       Impact factor: 3.940

Review 9.  Urine biomarkers in prostate cancer.

Authors:  Guillaume Ploussard; Alexandre de la Taille
Journal:  Nat Rev Urol       Date:  2010-01-12       Impact factor: 14.432

10.  Decreased urinary beta-defensin-1 expression as a biomarker of response to arsenic.

Authors:  Christine M Hegedus; Christine F Skibola; Marcella Warner; Danica R Skibola; David Alexander; Sophia Lim; Nygerma L Dangleben; Luoping Zhang; Michael Clark; Ruth M Pfeiffer; Craig Steinmaus; Allan H Smith; Martyn T Smith; Lee E Moore
Journal:  Toxicol Sci       Date:  2008-05-28       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.